Zobrazeno 1 - 10
of 37
pro vyhledávání: '"R. Bisegna"'
Autor:
Chiara Menin, Simona Agata, Luigi Chieco-Bianchi, Paolo Radice, G Cipollini, Laura Cortesi, Emma D'Andrea, Paolo Marchetti, Lara Della Puppa, Cristina D'Amico, Massimo Federico, Barbara Pasini, Valeria Pensotti, R. Bisegna, Silvano Presciuttini, Generoso Bevilacqua, Renato Mariani Costantini, Laura Ottini, Manuela Santarosa, M. Montagna, Sergio Ferrari, Corrado Ficorella, Davide Iandolo, Arcangela De Nicolo, C Ghimenti, Vittorio Silingardi, Paolo Aretini, Clelia de Giacomi, Daniela Turchetti, Siranoush Manoukian, Maria A. Caligo, Marco A. Pierotti, Enrico Ricevuto, Rosella Crucianelli, Fabio Marroni, Mauro Boiocchi, Alessandra Viel
Publikováno v:
ResearcherID
Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic heterogeneity may be present in both genes. We collected 179 pedigrees with identified germline mutation (104 BRCA1 and 75 BRCA2), ascertained in six co
Autor:
Corrado Ficorella, Alessandra Tessitore, G. P. De Rubeis, Enrico Ricevuto, Katia Cannita, T. Ventura, Z. C. Di Rocco, G. Porzio, R. Bisegna, F. De Galitiis, Stefano Martinotti, Paolo Marchetti
Publikováno v:
Annals of Oncology. 14:704-708
Background: Mutations in the p53 gene are the most common genetic alterations in human primary breast carcinoma and these mutations are often associated with worse prognosis and chemo/radioresistance. Patients and methods: The analysis of the p53 gen
Autor:
C. Z. Di Rocco, F. Calista, R. Bisegna, Paolo Marchetti, Corrado Ficorella, Enrico Ricevuto, Tina Sidoni, G. Porzio, G. Cianci
Familial breast cancer, whether associated or not with particular other breast cancer features (male, early onset, bilateral breast cancer), determines a wide and variable risk of developing breast cancer in the 'unpatients' (unaffected individuals)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccbd37cd90cec0f8f11ba5111d7e04a7
http://hdl.handle.net/11697/1479
http://hdl.handle.net/11697/1479
Publikováno v:
Cancer Research. 69:4092-4092
Background: Systematic reviews have found that LH-RH agonists are effective in the treatment of premenopausal women with early breast cancer. In an extended phase II study, 180 premenopausal women with HR-Pre-BC were treated with an LH-RH analogue in
Autor:
Francesco Recchia, C.O.C. Recchia, Silvio Rea, Giampiero Candeloro, Stefano Necozione, R. Bisegna
Publikováno v:
European Journal of Cancer Supplements. 7:301
Autor:
Giampiero Candeloro, R. Bisegna, P. Bonfili, Silvio Rea, Francesco Recchia, Stefano Necozione, G. Sica, Vincenzo Tombolini
Publikováno v:
Journal of Clinical Oncology. 27:3047-3047
3047 Background: The aim of this study was to evaluate the activity and toxicity of a multistep, sequential treatment including induction chemotherapy (ICT), consolidation chemoradiotherapy (CXRT), and maintenance immunotherapy (MI) in untreated pati
Autor:
R. Bisegna, Francesco Recchia, M. Sureda, Stefano Necozione, Silvio Rea, Massimo Bratta, Giampiero Candeloro
Publikováno v:
Journal of Clinical Oncology. 26:11541-11541
11541 Background: Randomized trials have established that ovarian suppression with luteinizing hormone-releasing hormone (LHRH) agonists is an effective adjuvant treatment in premenopausal patients with ER+ breast cancer, not inferior to chemotherapy
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Fabio Marroni, Generoso Bevilacqua, M. Montagna, Silvano Presciuttini, Paolo Aretini, Alessandra Viel, Sergio Ferrari, Enrico Ricevuto, Laura Cortesi, Maria A. Caligo, Manuela Santarosa, G Cipollini, Emma D'Andrea, R. Bisegna, Joan E. Bailey-Wilson, Giovanni Parmigiani
Publikováno v:
Scopus-Elsevier
Deleterious mutations of the BRCA1 and BRCA2 genes are a major risk factor for the development of breast and ovarian cancers.1–4 Mutation tests for these two genes commonly are now offered in specialised clinics.5,6 As a result, a large number of w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::980871974e45b4217b8c3f510de808ff
http://www.scopus.com/inward/record.url?eid=2-s2.0-11144356886&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-11144356886&partnerID=MN8TOARS
Autor:
Barbara Quaresima, Enrico Ricevuto, Francesco Baudi, Corrado Ficorella, Vito Barbieri, Serafino Conforti, Paolo Radice, Francesco Costanzo, Pierfrancesco Tassone, Cristina Grandinetti, Concetta M. Faniello, R. Bisegna, Giovanni Cuda, Paolo Marchetti, Salvatore Venuta, Alessandra Viel
Publikováno v:
Scopus-Elsevier
Several genes have been involved in the pathogenesis of hereditary breast/ovarian cancer (BOC), but mutations in the BRCA1 gene are by far the most recurrent. In this study, we report the identification of a founder mutation in a geographically and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089c5e12364ca993ee63a0633c74226e
http://www.scopus.com/inward/record.url?eid=2-s2.0-0035434628&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0035434628&partnerID=MN8TOARS